Ag-Bio Alliance With Monsanto Brings Alnylam Cash For “5x15” Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam will license its IP estate to agriculture giant Monsanto over 10 years, in turn getting a $29.2 million upfront payment that it will put toward further development of RNAi therapeutics.